Phase IIb Multi-center, Double-blind, Randomized, Parallel Group, Placebo Controlled Clinical Trial for the Assessment of Lipid Trends and Safety of RVX000222 in Statin Treated Subjects With Low Baseline HDL-C Concentrations.
Phase of Trial: Phase II
Latest Information Update: 04 Apr 2018
At a glance
- Drugs Apabetalone (Primary)
- Indications Coronary artery disease; Low HDL cholesterol
- Focus Therapeutic Use
- Acronyms SUSTAIN
- Sponsors Resverlogix Corporation
- 04 Apr 2018 Results (n=48) of post hoc analysis from SUSTAIN and ASSURE trials assessing the effects of pharmacologic epigenetic modulation on levels of ALP and kidney function via apabetalone published in the Kidney and Blood Pressure Research.
- 15 Nov 2017 Results of ASSERT, SUSTAIN and ASSURE trials assessing presented at the 90th Annual Scientific Sessions of the American Heart Association.
- 12 Oct 2017 Results of a pooled analysis from ASSERT, ASSURE, SUSTAIN trials (n = 798) published in the American Journal of Cardiovascular Drugs
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History